NEUROmuscular Training for Enhanced AGE Longevity
NEUROAGE
Improvement of Biological and Functional Longevity Through Advanced Neuromuscular Training Protocols and Resources in Adulthood.
2 other identifiers
interventional
390
1 country
1
Brief Summary
In recent years the research group on Prevention and Health in Exercise and Sport (PHES) has carried out numerous studies that have provided current and convincing evidence of the benefits of physical activity and exercise for chronic health, but unfortunately it has also shown that if physical exercise is not properly prescribed it can impair health, as well as accelerating the ageing process. The research proposal presented here aims to reveal some of the forms of physical exercise and resources for its application that may be most beneficial for people's health, thus trying to find reliable evidence that will increase healthy longevity and quality of life in society. Based on the above, and taking into account that the possible beneficial adaptations for health are specific to the applied form of physical exercise and the equipment used during its development, the PHES research group wishes to investigate the most appropriate strategies to ensure an active and positive ageing process. With these relevant findings the researchers can create specific action plans for prevention and promotion through physical exercise in order to improve both health and quality of life expectancy. The general objective of the project is to identify the most advanced methods and material resources with which to guarantee a beneficial process of active and healthy ageing with chronic training, so that with these relevant findings, concrete action plans can be created for prevention and promotion through physical exercise in order to improve both health and quality of life expectancy. The specific objectives are the following:
- To validate new, specific, safe, and efficient tools to monitor the intensity of neuromuscular strength training activities in older adults.
- To analyze and compare the chronic effects of different cardiovascular and neuromuscular strength training modalities applied with different materials on cellular ageing, body composition, metabolic, and immune profiles, cognitive function, motor function, quality of life and well-being in older adults.
- To evaluate the efficacy of the use of dietary supplements to reduce or even stop the chronic adverse effects that different physical activity levels and/or physical exercise programs can have on the oxidative and inflammatory profile, body composition and metabolic profile, muscle and DNA damage, and physical performance in older adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2024
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 24, 2024
CompletedFirst Submitted
Initial submission to the registry
September 18, 2024
CompletedFirst Posted
Study publicly available on registry
October 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 15, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 15, 2027
March 30, 2025
September 1, 2024
3.5 years
September 18, 2024
March 25, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Change in lipid peroxidation
The lipid peroxidation will be assessed via blood collections of 8-isoprostaglandin (nmol /mmol)
Baseline and 12-16 weeks
Change in antioxidants enzymes
The antioxidants enzymes will be assessed via blood collections of glutathione peroxidase (IU/g Hb).
Baseline and 12-16 weeks
Change in brain neuroplasticity
The brain neuroplasticity will be assessed via blood collections of brain-derived neurotrophic factor (BDNF) (ng/ml)
Baseline and 12-16 weeks
Change in inflammatory profile
The interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α) (pg/mL) will be assessed via blood collections.
Baseline and 12-16 weeks
Change in bone metabolism I (Formation)
The bone metabolism will be assessed via blood collections of Type I procollagen N-terminal propeptide (P1NP) are marker of bone formation.
Baseline and 12-16 weeks
Change in bone metabolism II (Resorption)
The bone metabolism will be assessed via blood collections of terminal telopeptide of collagen type I (β-CTX- 1) which is a marker of bone resoption.
Baseline and 12-16 weeks
Secondary Outcomes (12)
Change in blood pressure
Baseline and 12-16 weeks
Change in renal and hepatic profile I
Baseline and 12-16 weeks
Change in renal and hepatic profile II
Baseline and 12-16 weeks
Change in lipid profile
Baseline and 12-16 weeks
Change in metabolic profile I
Baseline and 12-16 weeks
- +7 more secondary outcomes
Other Outcomes (40)
Change in isokinetic muscle strength
Baseline and 12-16 weeks
Change in maximal muscle hand grip strength
Baseline and 12-16 weeks
Change in fracture risk
Baseline and 12-16 weeks
- +37 more other outcomes
Study Arms (12)
Water-based power resistance training + Dietary supplement I (WPowDSI)
EXPERIMENTALWater-based power resistance training + Placebo (WPowPl)
ACTIVE COMPARATORElastic band-based power resistance training + Dietary supplement I (EBPowDSI)
EXPERIMENTALElastic band-based power resistance training + Placebo (EBPowPl)
ACTIVE COMPARATORElastic band-based eccentric resistance training + Dietary supplement II (EBEccDSII)
EXPERIMENTALElastic band-based eccentric resistance training + Placebo (EBEccPl)
ACTIVE COMPARATORElastic band-based maximum strength resistance training + Dietary supplement II (EBMaxDSII)
EXPERIMENTALElastic band-based maximum strength resistance training + Placebo (EBMaxPl)
ACTIVE COMPARATORControl + Dietary supplement I (CDSI)
ACTIVE COMPARATORControl + Dietary supplement II (CDSII)
ACTIVE COMPARATORControl + Placebo (CPl)
PLACEBO COMPARATORAerobic training + Placebo (AerPl)
ACTIVE COMPARATORInterventions
The WPowDSI group will perform 8 repetitions per exercise (arm fly and swing, small and big kick, and a combined upper and lower limb exercise). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition) was recorded, accorded to an adaptation of the OMNI-RES scale in water in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase as fast as possible; eccentric phase 2s). Devices were used according to individual needs. Regarding supplementation, participants were randomly assigned to receive their daily dose.
The WPowCr group will perform 8 repetitions per exercise (arm fly and swing, small and big kick, and a combined upper and lower limb exercise). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition) was recorded, accorded to an adaptation of the OMNI-RES scale in water in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase as fast as possible; eccentric phase 2s). Devices were used according to individual needs. Regarding placebo, participants were randomly assigned to receive their daily dose.
The EBPowDSI group will perform 8 repetitions per exercise (militar press, squat, upright row, lunge, and push-press). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets and 90s of rest between exercises. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: as fast as possible; eccentric phase: 2s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
The EBPotPl group will perform 8 repetitions per exercise (militar press, squat, upright row, lunge, and push-press). Regarding the perceived exertion rating, a value of 4 (1º repetition,) and 7 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets and 90s of rest between exercises. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: as fast as possible; eccentric phase: 2s). Regarding placebo, participants were randomly assigned to receive their daily dose.
The EBEccDSII group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). The exercises were performed at maximum intensity until the point where stability or technique was lost, prior the stretching of the band. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: until reaching the stretching of the band; eccentric phase: 5s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
The EBEccPl group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). The exercises were performed at maximum intensity until the point where stability or technique was lost, prior the stretching of the band. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: until reaching the stretching of the band; eccentric phase: 5s). Regarding placebo, participants were randomly assigned to receive their daily dose.
The EBMaxDSII group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). Regarding the perceived exertion rating, a value of 7 (1º repetition,) and 9 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric-eccentric phase: 2s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
The EBMaxPl group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). Regarding the perceived exertion rating, a value of 7 (1º repetition,) and 9 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric-eccentric phase: 2s). Regarding placebo, participants were randomly assigned to receive their daily dose.
Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding placebo, participants were randomly assigned to receive their daily dose.
Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding supplementation, participants were randomly assigned to receive their daily dose.
Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding supplementation, participants were randomly assigned to receive their daily dose.
The group will perform aerobic exercise for 20-40 minutes with easy execution exercise. Regarding placebo, participants were randomly assigned to receive their daily dose.
Eligibility Criteria
You may qualify if:
- Sedentary adults (≥ 60 years), i.e., no physical exercise.
- Physically independent (able to walk 100 m without a walking aid and climb 10 steps without rest).
- Medical certificate of suitability or fitness to practice resistance training activities.
- Cognitive ability to understand and follow the instructions and sign the informed consent form.
- Free of any antioxidant supplements for at least six weeks before the start of this study: Vitamin C, Vitamin E, Vitamin A (beta-carotene), Zinc, Coenzyme Q (CoenzymeQ10), turmeric, Omega 3, creatine monohydrate or multivitamin products containing any of these compounds.
- Do not smoke more than 5 cigarettes per day or consume distilled alcoholic beverages on a daily basis.
You may not qualify if:
- Presence of cardiovascular, musculoskeletal, renal, liver, pulmonary, or neuromuscular and neurological disorders that would prevent the participant from performing the exercises.
- A history of malignant neoplasms.
- Terminal illness with life expectancy of less than one year.
- Mini mental State Examination lower than 23/30.
- Severe visual or hearing impairment.
- Body weight changes at 10% in the previous year.
- Intake of prescription medications or supplements (e.g., vitamins C, E) that were expected to alter the results of the study (ergogenic, dietary aids, estrogen, beta-blockers, steroid hormones, calcitonin, corticosteroids, glucocorticoids, thiazide diuretics, anticonvulsants, bisphosphonates, raloxifene).
- Current or prior (past six months) use of hormone replacement therapy.
- Engagement in regular strength training (more than once a week) during the previous six months.
- Participation in another research project (within the last six months) involving dietary, exercise, and/or pharmaceutical intervention.
- Not be under pharmacological treatment with allopurinol (trade name Zyloric).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Valencialead
- Generalitat Valencianacollaborator
- Indiex Sport Nutrition Spail SLcollaborator
Study Sites (1)
Physical Activity and Sport Science Faculty
Valencia, Valencia, 46020, Spain
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- CARE PROVIDER, OUTCOMES ASSESSOR
- Masking Details
- For masking the participants, the investigators will not inform participants of what group they will be in. For outcome assessor, data collectors and data analysts independent people will be use, and if this is not possible, a random code will be created for each participant so that it is not possible to identify which group belongs to.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Distinguished Chaired Full Professor of Physical Education and Sports
Study Record Dates
First Submitted
September 18, 2024
First Posted
October 1, 2024
Study Start
January 24, 2024
Primary Completion (Estimated)
July 15, 2027
Study Completion (Estimated)
July 15, 2027
Last Updated
March 30, 2025
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will not share